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Abstract 
A novel shuffled pig IL-2 gene and immunostimulatory sequences containing 11 CpG motifs were subcloned into the eukaryotic 
expression plasmid VR1020 and VR1012, respectively designated as the recombinant VRIL2S and VR1C, then they were 
encapsulated in chitosan nanoparticles (CNP) prepared by ionotropic gelation method. Forty 21-day-old piglets were divided into four 
groups and intramuscularly injected respectively with 0.5mg VRIL2S-CNP, VR1C-CNP, VR1020-CNP and CNP along with the 
rabbit-attenuated swine fever virus vaccines. The bloods were weekly collected from the piglets after vaccination to detect the changes 
of immunoglobulins, specific antibodies, interleukins, IFN-Ȗ and immune cells. The results were found that in comparison with the 
control VR1020-CNP and CNP group, the content of immunoglobulins, specific antibodies, IL-2, IL-6, IL-4 and IFN-Ȗ significantly 
increased in the sera from the treated VRIL2S-CNP and VR1C-CNP group (P<0.05); the numbers of lymphocytes and monocytes also 
remarkably elevated in the treated groups (P<0.05). Meanwhile, the levels of specific antibody, IgM, IgA and IgG in the VRIL2S-CNP 
group were significantly higher than those of VR1C-CNP group respectively from 7 or 28 to 56 days after vaccination (P<0.05); so did 
the amount of IL-2 and IFN-Ȗ in the VRIL2S-CNP group (P<0.05). Moreover, the number of lymphocytes and monocytes rose to 
different degrees in the VRIL2S-CNP treated pilglets compared to those of VR1C-CNP group (P<0.05). The average weight gain of in 
VRIL2S-CNP treated pigs was also obviously higher than that of the controls during the experimental period. These indicated that the 
humoral and cellular immunities of piglets were significantly promoted by VRIL2S-CNP and VR1C-CNP, and VRIL2S could 
provoked better immunities of piglets to Hog Cholera than VR1C-CNP, implying that the shuffled pig IL-2 gene entrapped with CNP is 
a safe and powerful adjuvant to boost the specific immunity of piglets against Hog cholera, facilitating the development of a novel 
effective adjuvant to improve the immunity of pig against Hog cholera.  
© 2010 Published by Elsevier Ltd.
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1. Introduction 
Classical swine fever virus (CSFV) is a small enveloped positive-stranded ribonucleic acid (RNA) virus belonging to 
the genus Pestivirus of the Flaviviridae family. It is a highly contagious pathogen affecting animals of the Suidae family 
and causes heavy losses in infected pig herds or wild boar populations all over the world (1) . Although the various 
attenuated Hog Cholera vaccines have been extensively employed to control the infection of CSFV, there are still lots of 
reports  on the emergence and epidemics of CSF in many countries. In addtion to the co-infection of pigs with other 
immunosuppressive pathogens, the inadequate immune responses in pigs to CSF vaccine is one of the most common 
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factors resutling in the failure of vaccination in developing areas. Therefore, the deficiency of CSF vaccination still 
inspire pressing exploration on more powerful vaccines and adjuvants for efficient control of CSF (2).  
In recent years, genes of interleukins, interferons, granulocyte-macrophage colony stimulating factors (GM-CF) and 
CpG motifs have been found to be the promising adjuvant due to their safety and effectiveness (3,4). IL-2 is well known 
to have a critical effect in enhancing humoral and cellular immunity in animals. However, the direct injection of IL-2 to 
enahnce the immunity of animal seems to encounter some problems, such as short half-life in vivo and possible severe 
side effects caused by high dosage IL-2 (5, 6, 7). Presently, the extensive explorations on DNA vaccination imply that the 
cytokine gene and specific oligodexoynucleotides (CpG motifs) can effectively promote the immunities of animals to 
various DNA vaccines.  
Up to now, although many researches have been focused on exploring new effective adjuvants to improve the 
immunity of animals to genetic vaccines (8), there still lack reports about the effect of pig IL-2 gene and CpG motifs on 
the immune responses of piglets to attenuated CSF vaccine. Therefore, the present experiment was firstly conducted to 
evaluate the effect of the eukaryotic plasmid of shuffled of pig interleukin-2 gene and CpG motifs in vivo on immunity of 
piglet for the sake of developing a safe and effective adjuvant to conventional vaccines to improve the control and 
prevention of Hog cholera. 
2. Materials and methods 
2.1. Conventional vaccine 
Rabbit-attenuated Swine fever virusChinese strain (C-strain provided by Chengdu Medicine and Appliances 
Factory, China) was employed in this experiment as conventional vaccines, which are extensively utilized to 
intramuscularly immunize swine in China to prevent infectious diseases. One dose for per pig vaccination is equal to 450 
rabbit fever units.   
2.2. Eukaryotic expression plasmids for shuffled of pig IL-2 and CpG 
The expression plasmids containing the shuffled pig IL-2 gene (IL2S) and CpG motifs had been prepared in our lab by 
inserting IL2S and CpG motifs into the expression VR1020 and VR1012 plasmid respectively under the control of the 
human cytomegalovirus promoter (CMV) using standard methods. The correct recombinant plasmids were identified by 
sequencing and named as VRIL2S and VR1C (9,10). 
2.3. Large-scale preparation of plasmid DNA 
Plasmid VRIL2S ,VR1C and VR1020 were used to inoculate 400 ml Lurea Bertani (LB) broth with kanamycin at 100 
ȝg/ml and shaken for 16 h at 37ƕC. Bacterial cells were pelleted by centrifugation and plasmid DNA extracted following 
large-scale alkine lysis. The plasmid was precipitated and purified by spermine method described as Jason (11). The 
residual contamination by endogenous toxin from E. coli was detected by use of  standard coagulation of Limulus 
Amebocyte lysate test (12) and the level of endogenous toxin in the plasmids was proved to be less than 0.1 EU/mg 
plasmid. Then, the plasmid DNA was resuspended in sterile saline water and stored at í200C until use. 
2.4. Preparation of chitosan-plasmid nanoparticles 
The polysaccharide chitosan glutamate was supplied by Chengdu Organic Chemicals Co. Ltd., CAS (95% deacylated, 
MW = 150 kDa). Chitosan nanoparticles (CNP) were prepared by ionotropic gelation method [13]. The chitosan solution 
(pH 5.5) and the solution of plasmid VR1C, VRIL2S and VR1020 (with the appropriate concentration of 
tripolyphosphate) was respectively heated in the 50ƕC water bath for 20 min, then an equal quantity of each plasmid 
solution and the CNP solution were gently mixed together for 5 min. The chitosan particles were observed with a 
transmission electronic microscope, and the granule diameter, dispersivity and Zeta potential of CNP were analyzed 
using a Zetasizer3000 HS/IHPL instrument (Malvern Instruments Ltd., Malvern, UK) (14). 
2.5. Animal vaccination 
Forty healthy 14-day old piglets, Landrace-Yorkshire-Chuanbai crossbreds, were randomly divided into four groups 
(A, B, C1 and C2) and with five males in each group. All the piglets were muscularly inoculated with 0.5mg the plasmids 
encapsulated in CNP or CNP alone, piglets in group A were injected with VRIL2S-CNP, group B with VR1C-CNP, group 
C1 with VR1020-CNP and group C2 with CNP. Simultaneously these four groups of piglets were intramuscularly 
injected with the same amount of Hog cholera vaccine (3 ml, 450 rabbit fever units attenuated CSFV per piglet). Blood 
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samples were collected from the piglets on days 0, 7, 14, 28, 42 and 56 after vaccination. All the pigs were bred under the 
same condition, and the initial and final weights of experimental pigs in each group were respectively recorded to 
compare the effect of inoculation on animal growth performance. The care and use of experimental piglets rationally 
complied with Chinese animal welfare laws, guidelines and regulations.  
2.6. Immunological assays 
2.6.1. Assays of IgG, IgM and IgA—sandwich ELISA 
Pig IgG, IgM and IgA quantization ELISA kits were purchased from Bethyl Laboratory (Inc., America) to detect the 
changes in immunoglobulins in the sera of experimental piglets. Briefly, 96-well flat-bottomed plates were coated with 
capture antibodies, goat anti-pig IgG, IgM or IgA and blocked with blocking buffer. Purified reference pig serum was 
diluted in sample diluent at various concentrations to produce a standard curve, which was included for each plate; and 
serial dilutions of piglet serum samples were added such that at least one value would fall within the range of the 
standard curve. Goat anti-pig secondary antibody was applied after washing, then antibody detection was completed 
with the addition of tetramethyl benzidine (TMB) substrate. The absorbance of the wells was determined at 450 nm 
using a Microplate Reader 3550 (Bio-rad, Hercules, California, US). 
2.6.2. Assay of specific antibody—SABC ELISA 
An indirect endpoint ELISA was performed to assess the titer of anti-CSFV antibody in the sera of piglets using the 
purified CSFV antigenic proteins (provided by Chengdu Medicine and Appliances Factory, China) to coat the plates. In 
short, 96-well flat-bottom plates (Nuclon, Roskilde, Denmark) were coated with the CSFV antigenic proteins (5ȝg/ml, 
diluted in coating buffer, 0.02 M sodium bicarbonate and pH 9.6) overnight at 4ƕC, and then serum samples of the 
piglets were 100-fold diluted in sample diluent (pH 7.4, 0.1M PBS and 1% BSA), and added into plates using 100 ȝl per 
well. After incubation at 37ƕC and washing five times, 100 ȝl of biotinated sheep anti-pig IgG diluted 1:1200 in sample 
diluent was added to each well and incubated for 1 h at 37ƕC. Subsequently 100 ȝl SABC (Strept-Avidin Biotin 
Complex, Boster Company,Wuhan, China) diluted in 1:1200 was added. Finally, 100 ȝl TMB substrate in 0.1 M 
phosphate–citrate buffer (pH 5.4) was added and incubated for 30 min at 37 ƕC, and the reaction was stopped with 2M 
H2SO4 (50 ȝl/well) and the absorbance was measured using the Microplate Reader 3550 (Biorad, Hercules, California, 
US) at 450 nm. 
2.6.3. Assay of interleukin 2, 4, 6 and interferons-Ȗ—sandwich ELISA 
To analyze the effects of recombinant plasmids on cytokine production of pig, the ELISA Kits (R&D Systems, Inc. 
614 McKinley Place NEMinneapolis, MN 55413) were used to detect the cytokine production in piglet serum. Assays 
were conducted according to the manufacturer’s protocol. The sera of the experimental piglets were applied to the ELISA 
plates pre-coated with mouse monoclonal antibody to pig IL-2, IL-4, IL-6 and IFN-Ȗ respectively. Recombinant pig IL-2, 
IL-4, IL-6 and IFN-Ȗ for generating standard curve and calibrating samples were respectively applied in two-fold serial 
dilutions. Biotinylated secondary antibody was diluted in sample diluents and added to plates using 100 ȝl/well and 
incubated for 1 h at 37 ƕC; 100 ȝl/well of Streptavidin-HRP diluted in sample diluents were added and incubated at room 
temperature for 30 min. Following washing, TMB substrate solution was added to each well and incubated at room 
temperature for 15 min, and then 50 ȝl of 2 M H2SO4 was used to stop the product formation. The absorbance of the 
wells was measured at 450 nm via a Microplate Reader 3550 (Bio-rad, Hercules, California, US), and the correction 
wavelength set at 540nm.  
2.7. Counting of immune cell of piglet 
The immune cells of piglets were counted using a routine method, the automatic counting of blood cells with 
Excell/TM 22 automatic blood cell counter (Denam company, USA). A blood smear was analysed with Giemsa staining 
to confirm the number of granulocytes, monocytes and lymphocytes. 
2.8. Statistical analysis 
Data from all groups were statistically compared by the statistical software program Systat 10 (SPSS). Differences 
between the groups were analyzed by the two way ANOVA and Tukey multiple comparison. Data were considered to be 
significantly different when P<0.05. 
3. Results 
3.1. Preparation of chitosan nanoparticles 
Observation with transmission electron microscope found that most of CNP were spherical. Analysis by Zetasizer 
3000 HS/IHPL showed that the average granule diameter was 156 nm (range from 110 to 235 nm), the diversity of 
nanoparticles was 0.198); zeta electricity potential was +17.86 mV, suggesting that the CNP was positively charged. 
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3.2. Changes of humoral immunity in the sera of piglets 
Fig.1 shows that the levels of IgG, IgM and IgA were significantly higher in the sera from groups A and B than those of 
groups C1 and C2 from 7 days after vaccination (P<0.05), and the amount of IgA, IgG and IgM significantly increased in 
VRIL2S-CNP treated piglets in comparison with the VR1C-CNP treated group from 28 to 56 days or 14 to 28 days post 
vaccination (P<0.05). Similarly, Fig.1c indicates that by 7 days after vaccination, specific antibody to CSF antigen could 
be detected, and the content of antibody was significantly raised in the sera of the piglets received VRIL2S and VR1C 
(groups A and B) compared with that of the control (groups C1 and C2) (P<0.05). Moreover, the level of specific antibody 
in the VRIL2S piglet were clearly higher than that of VR1C group from 14 to 56 days after vaccination (P<0.05).  
3.3. Changes of cytokines in the sera from vaccinated piglets 
Fig.2 demonstrates that compared with those of the controls (groups C1 and C2), the content of IL-2, IL-6 and IFN-Ȗ 
significantly increased in the sera from piglets injected with VRIL2S and VR1C (group A and B) from 7 to 56 days after 
vaccination (P<0.05); meanwhile, the IL-4 only significantly increased in the A and B groups from 14 to 28 days post 
vaccination  
(P<0.05), but the level of IL-4 did not show marked difference between group A and B (P>0.05). The levels of IL-2 
and IFN-Ȗ in group A were remarkably higher than those of group B after vaccination (P<0.05). In contrast, the content of 
IL-6 in the VR1C group was significantly higher than that of VRIL2S group from 14 to 28 days post vaccination 
(P<0.05).  
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Fig.1. The change of the humoral immunity in the sera of vaccinated piglets. a: The level of IgG in the group A and B were significantly higher than 
that of group C1 and C2 from 7 to 56 days post-vaccination (P<0.05), and the difference of IgG between groups A and B group was significant from 28 
to 56 days post vaccination (PV) (P<0.05). b: The content difference of IgM in the sera was significant between the treated piglets (group A and B) and 
the control (group C1 and C2) from 7 to 56 days PV (P<0.05). and the difference between group A and B groups was remarkable from 14 to 28 days 
PV (P<0.05). c: The amount of IgA in the sera of group A and B was significantly higher than that of the control group C1 and C2 from 7 to 56 days PV 
(P<0.05), and the difference of IgA between group A and B was significant from 28 to 56 days PV (P<0.05). d: The specific antibody in the sera of 
treated piglets significantli raised in comparison with those of the control group C1 and C2 (P<0.05), and the variance among group A and B was also 
significant after vaccination (P<0.05). 
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Fig.2. The change of the contents of cytokines in the sera of vaccinated piglets. a: The IL-2 level of group A and B were significantly higher than that 
of group C1 and C2 from 7 to 56 days PV (P<0.05), so was the difference among group A and B from 7 to 56 days PV (P<0.05). b: The significant 
increase of IL-4 appeared in the sera of group A and B in comparison with group C1 and C2 from 14 to 28 days PV (P<0.05). However, the difference 
in the level of IL-4 between group A and B was not significant (P>0.05). c: The IL-6 increased significantly in the sera of group A and B compared 
with that of the control C1 and C2 group from 7 to 56 days PV (P<0.05), and the IL-6 level of group B was remarkably higher than that of group A 
from 14 to 28 days PV (P<0.05). d: The IFN-Ȗ increased significantly in the sera of group A and B compared with that of group C1 and C2 from 7 to 56 
days PV (P<0.05), and the difference between group A and B was significant from 14 to 56 days PV (P<0.05). 
3.4. Changes of the number of immune cells in the blood 
It was observed from Fig.3 that the numbers of lymphocytes and monocytes significantly increased in the 
VRIL2S-CNP and VR1C-CNP group compared with the control groups (P<0.05); however, the differences between 
groups A and B were not remarkable after vaccination (P>0.05). The notable increases of granulocytes did not appear in 
the treated groups compared with that of the control groups(P>0.05), nor the differences between the treated groups or 
control groups (P>0.05).  
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Fig.3. The quantity change of immune cells in the blood of vaccinated piglets. a: The lymphocytes significantly mounted in the blood of group A and B 
compared with those of group C1 and C2 from 14 days PV (P<0.05, and the difference of lymphocytes between group A and B was not significant after 
vaccination (P>0.05). b: The monocytes significantly increased in the blood of treated piglets from group A and B compared with those of group C1 
and C2 after vaccination (P<0.05), whereas the difference of monocytes between group A and B was not remarkable (P>0.05). c: The granulocytes did 
not manifest significant increases in the blood of treated piglets (group A and B) in comparison with group C1 and C2 from 7 to 56 days PV (P>0.05), 
nor did the number of granulocytes between group A and B or group C1 and C2 (P>0.05). 
3.5. Effect on the growth performance of pigs 
The observation on growth performance of the pigs was started from the first day to sixty days after the inoculation. 
The results proved that the increase of growth performance in VRIL2S-CNP and VR1C-CNP was obviously higher than 
that of the controlsP<0.05, Table 1.  
Table 1  Effect on the weight gain of experimental pigs during 60 days observation n=10  
Group Initial weight (kg) End weight (kg) Net gain (kg) Average gain (kg) 
A 2.9±0.18 36.8±2.27 33.9±2.12 0.565a 
B 3.0±0.17 35.5±1.87 32.5±1.65 0.542a 
C1 3.2±0.21 32.3±2.33 30.1±1.97 0.502b 
C2 3.3±0.22 33.9±2.42 30.6±1.78 0.510b 
Note The data with the different superscript letter are significantly different (P<0.05), and vice versa(P>0.05).   
4. Discussion 
Oligodeoxynucleotides containing unmethylated CpGs (CpG motifs) have been extensicely proved to be 
immunostimulatory for different animals, and most of them were concentrated on evaluate the effects of synthetic 
unmethylated CpG motifs on the immunities of animals to genetic DNA vaccines. Up to now, due to the low bioactivity, 
short span life and possible serious side effects in vivo (15), the nake CpG motifs fails to be utilized in practical 
vaccination of pigs for the control of infectious diseases.  
In our early researches, VR1C-CNP had been found to be able to significantly enhance the immune responses in mice 
(10). In this report, the VR1C-CNP were firstly used to improve the immunity of piglet to rabbit-attenuated CSFV 
vaccine. The results were found that compared with the control groups, the VR1C significantly enhanced the humoral and 
cellular immunity in piglets to the attenuated virus vaccine, which was mirrored by the synergetic increases of 
immunoglobulin, specific antibodies, IL-2, IL-4, IL-6 and IFN-Ȗ in the blood of piglets in our experiment. Similarly, 20 
copies of CpG motifs were successfully utilized to boost the immunity to HIV-1 DNA vaccine in mice (16). These 
findings indicate that the multiple CpG motifs could be developed as a powerful adjuvant for animal vaccination.  
IL-2 is a pivotal cytokine for the activation of primary T-cell responses and essential for secondary T-cell 
responses(17), and it can strongly stimulate the proliferation of T cells and clonal expansion of antigen-specific T cells 
(18). Once even a small number of T cells are activated, they may secrete GM-CSF and other cytokines such as IFN-Ȗ 
and IL-2, and subsequently lead to the proliferation and activation of antigen presenting cells, which in turn can recruit 
more T cells to join immune defenses. Thus this positive feedback loop can result in strong cellular immunity. Besides, 
IL-2 can activate the proliferation of Th2 cells that can secrete other cytokines like IL-4 and IL-6 to stimulate the 
differentiation of B cells into plasma cells and memory cells, and promote the production of IgG, IgA, IgM (19). 
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Therefore, the enhancement of cytokines regulation, such as IL-2, IL-4 and IL-6, can finally lead to the significant 
promotion of specific immune responses in piglets.  
Although IL-2 protein has been proved to be a useful adjuvant to enhance immuity to viral vaccines (5), such as the 
PRRSV-ORF7 DNA vaccine in swine (20) and a DNA vaccine against Eimeria acervulina (21), the marked problems 
related with its in vivo enhancement of immunity against infections encourages more attempts to modify the IL-2 gene to 
enable lasting stable expression in vivo (22). In our previous study, It was found that the novel shuffled pig IL-2 protein 
displayed a remarkable increase of bioactivity compared to the wild-type pig IL-2, and the contents of immunoglobulins, 
interleukins and IFN-Ȗ significantly promoted in the mice inoculated with VRIL2S (9). But there is no report about 
whether the similar effect could be achieved in large animals. Herein, the effect of VRIL2S-CNP is firstly investigated on 
the immunity of piglet to rabbit-attenuated CSFV vaccine. Our results proved that compared with those of the controls, 
the significant enhancement of immunity of pig could be realized by realtively small amount of VRIL2S-CNP.  
In this study, several lines of evidence indicated that inoculation with VRIL2S-CNP and VR1C-CNP could 
successfully improve the systemic immunites of piglet in vivo. In VRIL2S and VR1C treated piglets, IL-2, IL-4, IL-6 and 
IFN-Ȗ showed significant increases in the sera in comparison with those of the control piglets (P<0.05). Similarly, the 
levels of IgG, IgA and IgM were also elevated in these piglets (P<0.05). Moreover, stronger specific antibody response 
was also observed in the tereated piglets (P<0.05). Meanwhile, the lymphocytes and monocytes significantly increased in 
the peripheral blood compared to the control groups (P<0.05). These results clearly demonstrated that both VRIL2S and 
VR1C were able to augment the immune responses to CSF vaccine, suggesting that VRIL2S-CNP and VR1C-CNP are 
effective adjuvants to boost the immunity of piglets against Hog cholera. 
Plasmids that express cytokines seem to be more efficient than the cytokine protein themselves in promoting the 
immune response of animals to vaccines in vivo. One possible reason is that the recombinant plasmid could consistently 
generate more cytokines in vivo to enhance the immunity of aniaml, including phagocytosis and presention of antigen to 
activated T and B cells, and elevation of cellular and humoral immune response (23,24). In addition, plasmids that 
express cytokines can be easily produced and stored. Therefore, cytokine genes with higher bioactivity and efficiency 
attract more and more attention for the development of novel effective adjuvants around the world. 
Chitosan is a natural polysaccharide used for the controlled delivery of drugs in vivo  and can be innocuously 
degraded by enzymes in animal (25). In order to improve the expression efficiency and protect IL-2 cDNA and CpG from 
degradation in vivo, the recombinant plasmids were enwrapped with chitosan nanoparticles. Recently, some reports had 
showed that, as a safe package molecules, chitosan nanoparticles could block the degradation of DNA by enzymes in 
vivo(26), promote DNA penetration into the target cells (27) and finally transfer it to the nucleus to promote gene 
expression (28). Therefore, it could be successfully applied as DNA carrier in immunotherapy. Obviously, in our 
experiments, the positively charged CNP with the recombinat plasmids could probably facilitate the entry and 
transfection of entrapped plasmids into target cells in vivo. 
Importantly, during the 60 days experimental observation period, all the treated piglets in VRIL2S-CNP and 
VR1C-CNP group actually did not manifest any local injuries or systemic symptoms, such as edema and inflammation at 
the injected spot, fever or loss of weight gain. In contrast, it was observed that the significant increases in the specific 
antibodies, immuoglobulins, cytokines, competent T lymphocytes in the treated piglets were maintained from 7 days to 
56 days post vaccination. This persistent enhancement of the immunity is also in accordance with the obvious 
improvement of weight gain of piglets received VRIL2S-CNP and VR1C-CNP treatment. Furthermore, our preliminary 
test had found that the integration of plasmid into animal genome could not be detected by PCR on 30 and 60 days post 
inoculation in the blood, spleen, muscle, heart, lung and liver of piglets injected with VRIL2S-CNP and VR1C-CNP(data 
in our lab), suggesting the genetic safety of VRIL2S-CNP and VR1C-CNP for pig. Based on these findings, 
VRIL2S-CNP is a potential novel promising immunopotentiator for enhancing the comprehensive immunity of pig to 
CSF vaccine. 
In conclusion, our experiment results demonstrated that VRIL2S-CNP could induce the better immune responses in 
piglets to CSF vaccine than VR1C-CNP, facilitating the preparation and application of safe and powerful adjuvant for the 
practical control of Hog cholera in the future.  
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